Alan N. Houghton
#137,623
Most Influential Person Now
Alan N. Houghton's AcademicInfluence.com Rankings
Alan N. Houghtonphilosophy Degrees
Philosophy
#7032
World Rank
#10179
Historical Rank
Logic
#4108
World Rank
#5359
Historical Rank

Download Badge
Philosophy
Alan N. Houghton's Degrees
- Doctorate Medicine University of California, San Francisco
Why Is Alan N. Houghton Influential?
(Suggest an Edit or Addition)Alan N. Houghton's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001) (2651)
- Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. (1999) (729)
- Monoclonal antibody therapy of cancer. (1990) (626)
- Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells (2004) (595)
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. (1985) (565)
- Focus on melanoma. (2002) (522)
- Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways (2000) (455)
- Cancer antigens: immune recognition of self and altered self (1994) (438)
- Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma (1992) (435)
- A new American Joint Committee on Cancer staging system for cutaneous melanoma (2000) (428)
- An Evidence‐based Staging System for Cutaneous Melanoma 1 (2004) (420)
- Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets (1982) (350)
- Fc receptors are required in passive and active immunity to melanoma. (1998) (346)
- Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. (2003) (335)
- Homozygous deletions within human chromosome band 9p21 in melanoma. (1992) (323)
- Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. (2011) (319)
- Coupling and Uncoupling of Tumor Immunity and Autoimmunity (1999) (260)
- Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. (2006) (259)
- Tumor immunity and autoimmunity induced by immunization with homologous DNA. (1998) (243)
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation (2010) (240)
- Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon (1984) (238)
- Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. (2003) (227)
- Heteroclitic Immunization Induces Tumor Immunity (1998) (224)
- Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens (1981) (219)
- Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. (2003) (219)
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (217)
- Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. (2000) (213)
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis (1993) (213)
- Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein (1995) (209)
- Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. (2006) (209)
- A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells (1999) (205)
- Immunity against cancer: lessons learned from melanoma. (2001) (204)
- Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial (2001) (190)
- The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product (1990) (189)
- Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen (1985) (185)
- Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. (2000) (183)
- Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA (1989) (180)
- Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. (1999) (180)
- A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase (1993) (180)
- Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity1 (2006) (176)
- Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. (1996) (174)
- Generation of human monoclonal antibodies reactive with cellular antigens. (1983) (168)
- Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75 (1995) (168)
- Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. (2003) (167)
- Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. (1988) (164)
- Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells (1987) (161)
- Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. (1985) (159)
- Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. (2006) (157)
- Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right (2009) (151)
- Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. (2003) (140)
- Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype (2012) (136)
- Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells (2004) (135)
- Immune recognition of self in immunity against cancer. (2004) (134)
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability (2013) (133)
- CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. (2004) (130)
- New TNM melanoma staging system: linking biology and natural history to clinical outcomes. (2003) (128)
- Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. (1998) (127)
- GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease (2004) (119)
- HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. (2001) (118)
- A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1 (2003) (117)
- Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. (1987) (114)
- T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. (2002) (111)
- Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma (1983) (110)
- Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. (2000) (110)
- Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. (1996) (109)
- Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. (1985) (109)
- Temozolomide plus thalidomide in patients with brain metastases from melanoma (2005) (108)
- Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. (2010) (108)
- Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide (2000) (107)
- Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity (2003) (105)
- Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response (2009) (104)
- Frequent p16-independent inactivation of p14ARF in human melanoma. (2008) (101)
- Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. (2007) (101)
- Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. (1982) (101)
- Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. (1993) (101)
- Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. (1988) (94)
- Autoimmunity and tumor immunity induced by immune responses to mutations in self (2006) (93)
- Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas (1992) (93)
- Monoclonal antibody therapies–a ‘constant’ threat to cancer (2000) (92)
- Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. (2006) (92)
- Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment (2017) (90)
- Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. (1987) (89)
- HDM2 protein overexpression and prognosis in primary malignant melanoma. (2002) (89)
- Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses (1986) (88)
- Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma (2008) (86)
- Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival (2007) (86)
- Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. (2009) (85)
- Malignant melanoma of the skin occurring during pregnancy (1981) (84)
- Systemic chemotherapy. (2000) (84)
- Multiple pathways to tumor immunity and concomitant autoimmunity (2002) (84)
- Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 (2007) (80)
- Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells1 (2000) (79)
- Evidence against Ha-ras-1 involvement in sporadic and familial melanoma (1987) (78)
- NCCN MELANOMA PRACTICE GUIDELINES (1998) (78)
- A melanosomal membrane protein is a cell surface target for melanoma therapy. (1996) (77)
- Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. (1991) (76)
- Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. (2002) (75)
- Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. (1997) (74)
- Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation (1988) (73)
- Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. (1991) (73)
- Immunity to cancer through immune recognition of altered self: studies with melanoma. (2003) (71)
- National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 (1993) (70)
- Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. (1999) (68)
- Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. (2002) (67)
- Anti‐melanoma effects of R24, a monoclonal antibody against GD3 ganglioside (1997) (67)
- Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. (1980) (66)
- Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody (1984) (66)
- Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo (2011) (66)
- Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. (1995) (65)
- Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. (2006) (64)
- Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells (1985) (63)
- A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. (1999) (62)
- Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity (2010) (61)
- FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. (2004) (61)
- FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor (2004) (61)
- Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. (1986) (60)
- Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles (2005) (60)
- Monoclonal antibodies: potential applications to the treatment of cancer. (1986) (60)
- Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. (1999) (59)
- A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma (2007) (58)
- Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. (1992) (57)
- Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination (2005) (56)
- Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. (1995) (55)
- Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma (2007) (53)
- INCREASED INCIDENCE OF MALIGNANT MELANOMA AFTER PEAKS OF SUNSPOT ACTIVITY (1978) (52)
- Evaluation of Elispot assays: influence of method and operator on variability of results. (2004) (52)
- Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. (1999) (51)
- Strategies to overcome immune ignorance and tolerance. (2002) (51)
- Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection (2010) (50)
- Purification of an autoantigenic 75‐kDa human melanosomal glycoprotein (1991) (50)
- Adjuvanticity of Plasmid DNA Encoding Cytokines Fused to Immunoglobulin Fc Domains (2006) (50)
- Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain (2006) (48)
- Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. (1997) (48)
- Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells (1983) (47)
- Sorting and secretion of a melanosome membrane protein, gp75/TRP1. (1997) (46)
- Xenogeneic DNA immunization in melanoma models for minimal residual disease. (2002) (46)
- Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. (2005) (45)
- Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3 (2008) (45)
- Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody (1984) (44)
- Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma (1994) (44)
- Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. (1992) (44)
- A phase I study of anti‐GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage‐colony stimulating factor in patients with metastatic melanoma (1995) (43)
- Rejection of mouse melanoma elicited by local secretion of interleukin‐2: Implicating macrophages without T cells or natural killer cells in tumor rejection (1995) (43)
- Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. (2000) (42)
- Treatment with high dose mouse monoclonal (anti‐GD3) antibody R24 in patients with metastatic melanoma (1992) (42)
- Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma (2006) (41)
- A T cell receptor associated with naturally occurring human tumor immunity (2007) (41)
- Solar radiation and malignant melanoma of the skin. (1981) (40)
- Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (39)
- Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. (1997) (39)
- Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. (1990) (39)
- Monoclonal antibody therapy of cancer. (1993) (38)
- Stuck in the MUC on the long and winding road (1998) (38)
- The Role of Homophilic Binding in Anti-tumor Antibody R24 Recognition of Molecular Surfaces (1999) (38)
- Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. (1990) (36)
- Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3) (1994) (35)
- Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. (2009) (34)
- Melanoma. Clinical practice guidelines in oncology. (2004) (34)
- The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. (2005) (33)
- GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. (2002) (33)
- Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma (2013) (33)
- Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. (2008) (33)
- Two Distinct Categories of Focal Deletions in Cancer Genomes (2013) (32)
- Granulocyte-macrophage colony-stimulating factor signals for increased glucose uptake in human melanoma cells. (1995) (32)
- Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain (2012) (31)
- Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG‐dependent cellular response (2008) (31)
- NCCN melanoma practice guidelines. National Comprehensive Cancer Network. (1998) (30)
- Acute hepatic vein thrombosis occurring during therapy for hodgkin's disease. A case report (1979) (30)
- Definition of tumor antigens suitable for vaccine construction. (1995) (30)
- Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation. (1995) (29)
- Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells (1982) (29)
- A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. (1992) (28)
- Establishment and characterization of two human myeloma cell lines secreting kappa light chains. (1989) (28)
- Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. (2009) (28)
- Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. (1996) (27)
- Gangliosides of T lymphocytes: evidence for a role in T-cell activation. (1990) (26)
- The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis (2004) (26)
- Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. (2007) (26)
- Insect cells as HLA-restricted antigen-presenting cells for the IFN-γ Elispot assay (2000) (25)
- CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. (2005) (25)
- Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. (2006) (25)
- Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. (2007) (25)
- Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine (2007) (25)
- Non-antibody immunotherapy of cancer. (1993) (25)
- Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins. (2001) (24)
- A phase II trial of high‐dose cisplatin and dacarbazine. Lack of efficacy of high‐dose, cisplatin‐based therapy for metastatic melanoma (1991) (23)
- Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. (1989) (23)
- OX 40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (23)
- The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum. (1998) (22)
- Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. (1996) (22)
- Medical treatment of metastatic melanoma. (1996) (21)
- Differentiation antigens of melanoma and melanocytes. (1986) (21)
- Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma: Cancer and Leukemia Group B 509901 (2006) (20)
- Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. (2002) (19)
- Mechanisms of immunization against cancer using chimeric antigens. (2008) (19)
- Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. (1994) (19)
- Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope (2011) (18)
- DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation1 (2006) (18)
- Recognition of Autoantigens by Patients with Melanoma (1993) (17)
- Immune rejection of mouse tumors expressing mutated self. (2009) (17)
- Current status of antitumor therapy with monoclonal antibodies. (1987) (16)
- Melanoma: Clinical practice guidelines in oncology™ (2006) (16)
- Mouse monoclonal IgG 3 antibody detecting GD 3 ganglioside : A phase I trial in patients with malignant melanoma ( complement activation / inflammation / immunotherapy ) (2003) (16)
- Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. (2001) (16)
- Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression (2007) (15)
- Estimates of stage‐specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma (2006) (15)
- Production and characterization of antibodies against human tyrosinase. (1994) (15)
- On course for a cancer vaccine (1995) (14)
- In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. (2006) (14)
- Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. (2000) (14)
- Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. (2011) (13)
- Vaccines and other adjuvant therapies for melanoma. (1998) (13)
- Surface antigens of human melanoma cells cultured in serum-free medium: induction of expression of major histocompatibility complex class II antigens. (1988) (13)
- Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent (2013) (12)
- R24 anti‐GD3 ganglioside antibody can induce co‐stimulation and prevent the induction of alloantigen‐specific T cell clonal anergy (1996) (12)
- Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications. (1988) (11)
- Mouse monoclonal antibody detecting G(D3) ganglioside: A phase I trial in patients with malignant melanoma (1985) (11)
- The Generation of Human Monoclonal Antibodies and Their Use in the Analysis of the Humoral Immune Response to Cancer (1985) (10)
- Purification of human melanocytes by monoclonal antibody combined with Percoll gradients. (1982) (10)
- Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. (2005) (10)
- Unconjugated Monoclonal Antibodies as Anticancer Agents (1991) (10)
- The role of lipopolysaccharide in T-cell responses following DNA vaccination. (2003) (10)
- A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle (2007) (10)
- Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. (1995) (10)
- LIGHTing the way for tumor immunity (2004) (9)
- The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease (2008) (9)
- Macrophage colony-stimulating factor: biological effects and potential applications for cancer therapy. (1991) (8)
- Microenvironment and Immunology Monocytic CCR 2 þ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD 8 T-cell In fi ltration into the Tumor Microenvironment (2012) (8)
- Phenotypic heterogeneity of melanoma. (1988) (8)
- Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner1 (2006) (8)
- Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag. (2007) (8)
- Cell surface antigens of melanocytes and melanoma. (1985) (8)
- Antigens of melanocytes and melanoma (1991) (8)
- Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside. (1989) (8)
- Analysis of hybridoma-exchange antibodies. (1982) (8)
- Cutaneous Melanoma, 4th Edition (2005) (7)
- Molecular abnormalities in the expression of HLA class‐I antigens by melanoma cells (1991) (7)
- Three human cell surface antigen systems determined by genes on chromosome 12 (1984) (7)
- Building a better monoclonal antibody. (1988) (7)
- Assignment of the DPP4 gene encoding adenosine deaminase binding protein (CD26/dipeptidylpeptidase IV) to 2q23. (1994) (7)
- Antigens Expressed by Melanoma and Melanocytes (1987) (7)
- Solar cycles and malignant melanoma. (1979) (6)
- Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. (1994) (6)
- Development of effective vaccines for old mice in a tumor model. (2009) (6)
- Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (5)
- Tumor immunology (1991) (5)
- CD 8 + T-Cell – Dependent Immunity Following Xenogeneic DNA Immunization against CD 20 in a Tumor Challenge Model of B-Cell Lymphoma (2004) (5)
- Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody (1994) (5)
- Faculty Opinions recommendation of Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. (2007) (5)
- Monoclonal antibody therapy. (1992) (5)
- Faculty Opinions recommendation of Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. (2006) (4)
- The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes. (1983) (4)
- Monoclonal antibodies for the treatment of cancer: therapeutic strategies. (1989) (4)
- Human monoclonal antibodies recognizing intermediate filament (IF) molecules (1984) (4)
- Immunoperoxidase staining of early human melanoma colonies with monoclonal antibodies. A new method for in vitro antigenic-morphologic correlation. (1984) (3)
- Monoclonal antibodies in the treatment of hematopoietic malignancies. (1988) (3)
- Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas (1993) (3)
- Current Status of the Search for Melanoma-Specific Antigens (1981) (3)
- Melanoma in Connecticut. (1978) (3)
- 48 Phase I study of HSPPC-96 (oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma (2003) (3)
- HDM 2 Protein Overexpression , but not Gene Amplification , is Related to Tumorigenesis of Cutaneous Melanoma 1 (2001) (2)
- Chapter 36 – Molecular Biology of Melanoma (2008) (2)
- Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas (1992) (2)
- Identification of differentiation antigens of melanoma and melanocytes by mouse and human monoclonal antibodies. (1984) (2)
- Phase II trial of cisplatin and etoposide in patients with metastatic melanoma (1991) (2)
- Monoclonal antibody therapy for cancer. (1991) (2)
- apoptosis in response to the combination of bortezomib and SAHA Myc regulates aggresome formation, the induction of Noxa, and (2013) (2)
- Phase I & Ib Trials of Murine Tyrosinase ± Human GM‐CSF DNA Vaccination in Dogs with Advanced Malignant Melanoma (2005) (2)
- Immunotherapy with monoclonal antibodies in metastatic melanoma (1992) (2)
- DNA-Based Cancer Vaccines (2002) (2)
- Solar radiation and cutaneous melanoma. (1982) (2)
- Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness (2021) (2)
- Monoclonal antibody therapy of cancer. (1991) (1)
- Abstract 4742: Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma (2011) (1)
- Analysis of the Humoral Immune Repertoire in Patients with Cancer (1987) (1)
- Immune response of cancer patients: Analysis with human monoclonal antibodies (1984) (1)
- Class ificat ion of Clear-Cel l Sarcoma as a Subtype of Melanoma by Genomic Profil ing (2003) (1)
- Antibodies: A Laboratory Manual edited by Ed Harlo and David Lane, Cold Spring Harbor Laboratory, 1988. $50.00 (xiii + 726 pages) ISBN 0 87969 314 2 (1989) (1)
- An agonist anti-GITR antibody enhances effector and memory CD8 T cell responses and tumor immunity following xenogeneic DNA immunization against melanoma (2005) (1)
- Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies (1985) (1)
- Related to Tumorigenesis of Cutaneous Melanoma HDM 2 Protein Overexpression , but not Gene Amplification , is Updated (2001) (1)
- Times are a changin': the era of peptide immunization begins. (1997) (1)
- Phase II evaluation of chlorozotocin in patients with malignant melanoma. (1981) (1)
- Antiviral T cell responses (2005) (1)
- Xenogeneic Human Tyrosinase DNA Vaccination Induces Specific Immune Response in Dogs with Advanced Malignant Melanoma (2005) (1)
- Cancer immunology (1993) (1)
- Blockade of surface bound TGF-β on regulatory T cells abrogates suppression of effector T cell function within the tumor microenvironment (TUM2P.1015) (2015) (1)
- Specific Active Immunization Against Cell Surface Antigens of Human Malignant Melanoma: Development of an Approach (1981) (0)
- Abstract 1971: Concurrent loss of PTEN and RB is sufficient to confer BRAF independence in melanomas harboring V600E BRAF mutations (2010) (0)
- Temozolomide Plus Thal idomide in Pat ients With Advanced Melanoma : Resul ts of a Dose-Finding Tria l (2002) (0)
- Alphavirus replicon particles expressing melanocyte differentiation antigens are effective vaccines for melanoma (41.55) (2009) (0)
- Phase II trial of N-methylformamide in patients with metastatic melanoma (1991) (0)
- Erratum (2005) (0)
- The T Cell Cytolytic Molecules Fas Ligand And Trail, The Trafficking Molecules CCR9, β7 Integrin And PSGL1, And The Immune Modulating Molecules OX40 And Ceacam1 Are Required For Thymic Graft-Versus-Host Disease (2009) (0)
- Classification o f C lear-Cell S arcoma a s a S ubtype o f M elanoma by G enomic P rofiling (2003) (0)
- Faculty Opinions recommendation of Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. (2004) (0)
- Treatment of Malignant Melanoma with a Mouse Monoclonal IgG3 Antibody Detecting the Ganglioside GD3 (1986) (0)
- B cell deficient mice reject B16 melanoma via T cell mediated immunity that is not associated with autoimmunity (2000) (0)
- Faculty Opinions recommendation of Initial T cell frequency dictates memory CD8+ T cell lineage commitment. (2005) (0)
- Antibody Reactivity to Cell Surface and IntraceUular Antigens (2003) (0)
- Faculty Opinions recommendation of DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. (2007) (0)
- DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution. (2004) (0)
- Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection (2007) (0)
- ADENOSINE DEAMINASE EXPRESSION BY MELANOCYTES (2003) (0)
- CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (2009) (0)
- Xenogeneic DNA vaccination prevents metastasis in a melanoma model of minimal residual disease (2000) (0)
- Abstract B87: Genomic complexity and BRAF/MEK‐dependence in V600E BRAF mutant melanoma (2009) (0)
- Monoclonal antibody therapy of cancer. (1991) (0)
- DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). (2004) (0)
- Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase : A Phase I Trial 1 (2003) (0)
- Thirty Years of Advances in Melanoma (2009) (0)
- TGF-β dependent suppression of effector T cell function within the tumor microenvironment (P2033) (2013) (0)
- Stage specific survival is altered by the changes in the 2002 AJCC staging for melanoma (2005) (0)
- Milieu Is Right Regulatory T Cell Expansion if the Cytokine Cutting Edge: OX40 Agonists Can Drive (2009) (0)
- Inflammation and immunity: approaches to immunotherapy in melanoma (1993) (0)
- Faculty Opinions recommendation of Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. (2005) (0)
- Chapter 17 Human Monoclonal Antibodies Humoral Immune Response in Patients with (1985) (0)
- Effect of self antigen specific CD4+ T cell precursor frequency on the anti-tumor immune response: Implications for adoptive T cell therapy (P2040) (2013) (0)
- Faculty Opinions recommendation of Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. (2001) (0)
- Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody. (2007) (0)
- Monoclonal antibodies and immobilized antibodies (1987) (0)
- A role for the GITR pathway in anaphylaxis (P4326) (2013) (0)
- 337 Evaluation of the immunogenicity of selected doses of BEC2 plus BCG after initial therapy for small cell lung cancer and report of long survival of immunized patients (1997) (0)
- Faculty Opinions recommendation of Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma (2005) (0)
- Immunologic Study of Tumors in Mouse Models (2004) (0)
- Melanoma tumor antigen and autologous antibody (1986) (0)
- Differentiation Antigen Immunization Against a Tumor Cancer Immunity After Xenogeneic DNA A Single Heteroclitic Epitope Determines (2003) (0)
- Xenogeneic immunization with tyrosinase DNA vaccines: results from clinical trials in humans and dogs (2006) (0)
- XENOGENEIC DNA IMMUNIZATION WITH TYROSINASE RELATED PROTEIN-2 BREAKS TOLERANCE: DEFINING SPECIFIC MECHANISMS IN AUTOIMMUNITY AND TUMOR IMMUNITY (1999) (0)
- Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment (2014) (0)
- Biologic basis for monoclonal antibodies in cancer treatment (1987) (0)
- Chapter 13 The biology of human melanoma (1996) (0)
- Gp75 as a tumor vaccine against melanomas (1991) (0)
- FAB FRAGMENT FROM MURINE ASCITES (1999) (0)
- Genetic cancer vaccines: 488 (1997) (0)
- Antibody and CD 8 + TCell Responses against HER 2 / neu Required for Tumor Eradication after DNA Immunizationwith a Flt-3 Ligand FusionVaccine (2007) (0)
- 791 Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model (2022) (0)
- Monoclonal antibody therapy of cancer. (1991) (0)
- Abstract 4167: Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model (2022) (0)
- Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment (2013) (0)
- Antitumor Immunity Differentiation Antigens and Enhances Tolerance/Ignorance to Melanoma Family Related Gene Activation Overcomes Glucocorticoid-Induced TNF Receptor (2006) (0)
- Agonist anti-GITR antibody synergizes with cyclophosphamide (CTX) to induce tumor immunity (2008) (0)
- Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma (1999) (0)
- Abstract #5657: Agonist anti-GITR monoclonal antibody targets both regulatory and effector T cells to induce tumor immunity (2009) (0)
- The T Cell Cytolytic Molecules FasL and TRAIL are Required for Thymic GVHD (141.14) (2009) (0)
- Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies : Identification of astrocytoma subsets ( hybridoma / differentiation antigens / glial fibrillary acidic protein ) (2003) (0)
- Faculty Opinions recommendation of In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. (2003) (0)
- Chromosomal instability in mouse metastatic pancreatic cancer— it's Kras and Tp53 after all (2005) (0)
- Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2 μmRNA: 38 (1993) (0)
- Genetic variation at MC1R, GSTT1, and GSTM1 may increase risk for melanoma (1999) (0)
- Cancer Immunity, Vol. 5, p. 2 (1 February 2005) (2005) (0)
- Abstract A43: Therapeutic efficacy of antitumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells. (2013) (0)
- TransplantationAllogeneic Hemopoietic Stem Cell Antigens Enhances Tumor Immunity after DNA Immunization against Tissue-Restricted (2006) (0)
- MULTIPLE KINASE INVOLVEMENT IN THE ACTIVATION OF HUMAN PERIPHERAL BLOOD T LYMPHOCYTES WITH AN ANTI-GANGLIOSIDE (GD3) MONOCLONAL ANTIBODY (mAb) (1993) (0)
- In Vitro Expansion of Antigen-Specific Cytotoxic T Lymphocytes by HLA-A*0201 Transfected K562 for Monitoring of T-cell Responses (2005) (0)
- A Perspective on Cancer Immunology and Immunotherapy (2007) (0)
- Raising Monoclonal Antibodies Monoclonal Antibody-Based Therapy of Cancer Edited by Michael L. Grossbard New York: Marcel Dekker (1998). 464 pp. $185.00 (1999) (0)
- CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (40.33) (2009) (0)
- Patent Number : 5 , 389 , 530 45 Date of Patent : Feb . 14 , 1995 GD 3 ganglioside : A phase I trail . . . melanoma ' (2017) (0)
- Faculty Opinions recommendation of Lymphangiogenic gene therapy with minimal blood vascular side effects. (2002) (0)
- Cell-Mediated Immunity to Cancer (2002) (0)
- Cancer Immunity, Vol. 5, p. 4 (4 March 2005) (2005) (0)
- Transformation of human melanocytes in vitro (1986) (0)
- Phase I I S tudy o f T emozolomide P lus T halidomide f or t he Treatment o f M etastatic M elanoma (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan N. Houghton?
Alan N. Houghton is affiliated with the following schools: